Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, triggering a 30% stock drop.

In this week's EuroBiotech Report, BMJ warns of Trump effect, Nanovector stokes takeover talks, Apitope advances Merck KGaA reject and more.

In our EuroBiotech roundup this week, Roche extends antibiotic collaboration, Big Pharma venture backs academic projects and Neovacs pens China pact.

Celiacs could be freed from the gluten-free aisle of the supermarket if a therapeutic approach developed by ImmusanT proves effective in trials.

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Topspin Biotech Fund (…

Apitope has posted phase 2a data on the multiple sclerosis drug Merck KGaA walked away from last year.

VBL Therapeutics has presented more data from a phase 2 trial of VB-111 monotherapy in thyroid cancer patients.

Cidara Therapeutics will stop work on its antifungal CD101 in women with acute VVC, after the topical candidate failed a mid-stage trial.

Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval.

Biotech